Abstract: Objective To explore the role of long-chain non-coding RNA H19 ( lncRNA H19) in bortezomibresisted multiple myeloma ( MM) . Method Twenty six newly diagnosed MM patients, 25 chemotherapy relieves MM patients, and 22 bortezomib-resisted MM patients were selected. The human multiple myeloma OPM2 cells were transfected by siRNA-H19 and lentivirus. lncRNA H19 was detected by Real-time PCR analysis. The sensitivity of OPM2 cells to bortezomib was detected by CCK-8 cell viability analysis. Result The 2^{-△ △ Ct} values of lncRNA H19 in the control group, the newly diagnosed MM group, the remission MM group and the drug-resistant MM group were (0. 107±0. 032) , (0. 324±0. 067) , (0. 218±0. 042) , and (0. 486±0. 095) , respectively. There were significant differences among these groups ( P < 0. 01) . Which was significantly higher in MM patients than those in the control group (P<0. 01) , in the newly diagnosed MM patients than those in the remission MM patients ( P<0. 01) , and in the drug-resistant MM patients than those in the newly diagnosed MM patients (P<0. 01) . The IC₅₀ values of bortezomib to the control group, the OPM2 / si-H19 group, the OPM2 / NC group, the OPM2 / H19 group and the OPM2 / Blank group were ( 17. 86 ± 1. 64) nmol / L, ( 6. 83 ± 1. 05) nmol / L,( 18. 04 ± 1. 72) nmol / L, (31. 14±3. 57) nmol / L and (17. 75±1. 68) nmol / L, respectively. There were no significant differences among the control group, the OPM2 / NC group, and the OPM2 / Blank group ( P> 0. 05) . The IC₅₀ values were lower in the OPM2 / si-H19 group than that in the control group, and in the control group than that in the OPM2 / H19 group (P<0. 01) . Conclusion High expression of lncRNA H19 may be involved in bortezomib resistance.

multiple myeloma ( MM ) , bortezomib, long-chain non-coding RNA H19 ( lncRNA H19 ) ;drug resistance